Press release
Cutaneous Squamous Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Cutaneous Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Cutaneous Squamous Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cutaneous Squamous Cell Carcinoma Pipeline Report
* In February 2025:- Rakuten Medical Inc.:- Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
* In February 2025:- Hummingbird Bioscience :- This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous Non-Small Cell Lung Cancers, and HMBD-001 in combination with cetuximab in participants with advanced Squamous Cell Cancers.
* In February 2025:- GV20 Therapeutics:- This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care. This is a Phase 1/2A non-randomized, open label, multi-center study to be conducted in four parts (Parts A, B, C and D).
* DelveInsight's Cutaneous Squamous Cell Carcinoma pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Cutaneous Squamous Cell Carcinoma treatment.
* The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
* Promising Cutaneous Squamous Cell Carcinoma Therapies such as MK-3475A, L19IL2 +L19TNF, Cemiplimab, Everolimus, Sirolimus, and others.
Stay informed about the cutting-edge advancements in Cutaneous Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Squamous Cell Carcinoma Emerging Drugs
* HLX 07: Shanghai Henlius Biotech
HLX07 is a bio-better independently developed by Henlius. Adopting the self-developed advanced antibody engineering platform, Henlius re-engineered cetuximab by humanizing its Fab regions and minimizing its glycan contents to generate HLX07 to reduce the immunogenicity and increase the affinity of the product. Pre-clinical studies have shown that HLX07 binds EGFR with similar affinity and had better bioactivity compared to cetuximab. Henlius holds patents of HLX07 in several jurisdictions including China, the United States, the European Union, Australia, and Japan. Moreover, Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
* Opzelura: Incyte Corporation
Opzelura, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
* RM 1995: Rakuten Medical
RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor -chain (CD25) and IRDye Registered 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light. Rakuten Medical's preclinical data has suggested that RM-1995 photo immunotherapy treatment can be utilized to specifically deplete intratumoral Tregs, thereby alleviating local Treg-mediated restraint within the tumor microenvironment, rapidly improving the CD8 T cell: Treg ratio, and reinvigorating effector CD8+ T cell responses. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.
The Cutaneous Squamous Cell Carcinoma pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous Squamous Cell Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous Squamous Cell Carcinoma Treatment.
* Cutaneous Squamous Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cutaneous Squamous Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous Squamous Cell Carcinoma market.
Learn more about Cutaneous Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Cutaneous Squamous Cell Carcinoma Research and development projects @ Cutaneous Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Squamous Cell Carcinoma Companies
Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
Cutaneous Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Cutaneous Squamous Cell Carcinoma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Cutaneous Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology disease @ Cutaneous Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cutaneous Squamous Cell Carcinoma Pipeline Report
* Coverage- Global
* Cutaneous Squamous Cell Carcinoma Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
* Cutaneous Squamous Cell Carcinoma Therapies - MK-3475A, L19IL2 +L19TNF, Cemiplimab, Everolimus, Sirolimus, and others.
* Cutaneous Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cutaneous Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous Squamous Cell Carcinoma Pipeline on our website @ Cutaneous Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/cutaneous-squamous-cell-carcinoma-cscc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cutaneous Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cutaneous Squamous Cell Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HLX 07: Shanghai Henlius Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RM 1995: Rakuten Medical
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Cutaneous Squamous Cell Carcinoma Key Companies
* Cutaneous Squamous Cell Carcinoma Key Products
* Cutaneous Squamous Cell Carcinoma- Unmet Needs
* Cutaneous Squamous Cell Carcinoma- Market Drivers and Barriers
* Cutaneous Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Cutaneous Squamous Cell Carcinoma Analyst Views
* Cutaneous Squamous Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cutaneous-squamous-cell-carcinoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hernia-repair-devices-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Squamous Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3886636 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
